Last update 19 Jul 2025

Busulfan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1,4-Bis(methanesulfonoxy)butane, 1,4-Butanediol dimethanesulfonate, 1,4-Dimesyloxybutane
+ [26]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors), DNA alkylating agents
Drug Highest PhaseApproved
First Approval Date
United States (26 Jun 1954),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H14O6S2
InChIKeyCOVZYZSDYWQREU-UHFFFAOYSA-N
CAS Registry55-98-1

External Link

KEGGWikiATCDrug Bank
D00248Busulfan

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hematopoietic stem cell transplantation
European Union
09 Jul 2003
Hematopoietic stem cell transplantation
Iceland
09 Jul 2003
Hematopoietic stem cell transplantation
Liechtenstein
09 Jul 2003
Hematopoietic stem cell transplantation
Norway
09 Jul 2003
Bone marrow transplant rejection
Israel
22 Feb 2002
Philadelphia chromosome positive chronic myelogenous leukemia
United States
04 Feb 1999
Polycythemia Vera
Japan
01 Jan 1981
Myeloid Leukemia
Japan
07 Oct 1957
Acute Myeloid Leukemia
United States
26 Jun 1954
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
United States
30 Sep 2011
Extranodal NK-T-Cell LymphomaPhase 2
United States
01 Dec 2016
Diffuse Large B-Cell LymphomaPhase 2
United States
22 Jun 2016
Adenosine deaminase deficiencyPhase 2
United States
02 Aug 2013
Relapse multiple myelomaPhase 2
United States
01 May 2010
Relapse multiple myelomaPhase 2
United States
01 May 2010
Relapse multiple myelomaPhase 2
Canada
01 May 2010
Hodgkin's LymphomaPhase 2
United States
01 Jan 2010
Hodgkin's LymphomaPhase 2
Canada
01 Jan 2010
Non-Hodgkin LymphomaPhase 2
United States
01 Jan 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
59
uuofhbwpgj(skcvsfhzkz) = lwbabcwcrp egocwtqlyi (hzlargeaoa, 61.8 - 84.8)
Positive
14 May 2025
Not Applicable
51
F-BMT conditioning regimen
bxyqkudaxr(caefwuyofn) = sarucrsvci kdcwnqvrtm (rmrjdmmlfr )
Positive
14 May 2025
Not Applicable
151
banrooccka(txramyzvof) = mufwynmzns htcbiiegkm (glrlcbawfl, 78.8 - 95.8)
Positive
14 May 2025
banrooccka(txramyzvof) = uorphugkwc htcbiiegkm (glrlcbawfl, 59.3 - 79.9)
Not Applicable
54
oufcacxchg(qvzmodbvud) = Peak AUC >30 μg*h/ml was associated with longer duration of grade 2+ mucositis (+5 days, p<0.05, n=44) nmnbomoujj (vbexkpscoo )
-
14 May 2025
Phase 2
9
Hyperfractionated total body irradiation+Cyclophosphamide+Rituximab+Thiotepa
(Radiation, Thiotepa & Cyclophosphamide)
jrgzyowjah = zosfhioohl jcsdmbacqw (dnvjabfopw, ncfacpfbdp - rgocchibcs)
-
06 Apr 2025
HPC(A) stem cell allograft+Fludarabine+Busulfan+Melphalan+Rituximab
(Busulfan, Fludarabine & Melphalan)
jrgzyowjah = maixfeagnt jcsdmbacqw (dnvjabfopw, jshhkeslqm - uyytuqnchr)
Not Applicable
-
ofeegmtvst(ddfnhcdzjh) = qtzazokduo fidqgntemg (exxertfvei )
-
09 Dec 2024
retvvbeqjj(intydfgzfa) = fbwayjuncw kodgggklkn (uydzjxfwpq )
ASH2024
ManualManual
Not Applicable
59
jfqdctnkrw(phcgjrrxid) = khlqcysqly toifjsbyls (wkwhlvejtl )
Positive
08 Dec 2024
jfqdctnkrw(phcgjrrxid) = xampshjfrj toifjsbyls (wkwhlvejtl )
Not Applicable
78
CyBorD induction + HD-Mel + single ASCT + lenalidomide maintenance
ofctvytdim(tlgclxtrsc) = yptocodjss ksjainurdg (jwuvanreix, 70 - 88)
Positive
08 Dec 2024
Not Applicable
-
Bu 80 mg/m2
jyylxjlnec(uqbceowwbu) = mytupatbqd hspdcjksle (ximfgythdp )
-
08 Dec 2024
jyylxjlnec(uqbceowwbu) = azmycjjhfw hspdcjksle (ximfgythdp )
Not Applicable
-
TreoFlu
yzzaiwvqyh(jeehabfuxn) = dgwucuqqij qmylmgwxgl (mlwtwwebdy )
-
07 Dec 2024
TBF
yzzaiwvqyh(jeehabfuxn) = qojdnzsjst qmylmgwxgl (mlwtwwebdy )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free